Zealand announces that Sanofi has submitted LixiLan for regulatory review in the US, triggering a USD 20 million milestone payment

The regulatory submission is an important step towards potentially making LixiLan available as a new treatment option for adult Type 2 diabetes patients in the US

Recommended
deficit cut